Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

PhaseBio Pharmaceuticals Inc (PHAS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow PhaseBio Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PhaseBio Pharmaceuticals historical data, for real-time data please try another search
0.070 -0.025    -26.21%
02/11 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 8,811,099
  • Bid/Ask: 0.056 / 0.070
  • Day's Range: 0.067 - 0.092
PhaseBio Pharmaceuticals 0.070 -0.025 -26.21%

PHAS Balance Sheet

 
Featured here, the Balance Sheet for PhaseBio Pharmaceuticals Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2022
30/06
2022
31/03
2021
31/12
2021
30/09
Total Current Assets 11.56 27.57 48.78 65.24
Cash and Short Term Investments 7.8 18.69 41.8 56.36
Cash - - - -
Cash & Equivalents 7.8 18.69 41.8 56.36
Short Term Investments - - - -
Total Receivables, Net - - - -
Accounts Receivables - Trade, Net - - - -
Total Inventory - - - -
Prepaid Expenses 3.76 8.88 6.98 8.88
Other Current Assets, Total - - - -
Total Assets 22.17 38.66 60.54 77.72
Property/Plant/Equipment, Total - Net 10.54 11.04 11.7 12.43
Property/Plant/Equipment, Total - Gross 15.67 15.56 15.62 15.74
Accumulated Depreciation, Total -5.12 -4.52 -3.92 -3.31
Goodwill, Net - - - -
Intangibles, Net - - - -
Long Term Investments - - - -
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 0.058 0.06 0.06 0.06
Other Assets, Total - - - -
Total Current Liabilities 24.68 21.69 27.88 21.46
Accounts Payable 6.32 6.78 12.57 8.52
Payable/Accrued - - - -
Accrued Expenses 12.46 7.89 8.35 6.12
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 4.5 5.42 5.41 5.4
Other Current liabilities, Total 1.4 1.59 1.55 1.41
Total Liabilities 139.56 141.06 153.57 128.05
Total Long Term Debt - - 1.36 2.72
Long Term Debt - - 1.36 2.72
Capital Lease Obligations - - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 114.88 119.37 124.33 103.88
Total Equity -117.4 -102.39 -93.03 -50.33
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.05 0.05 0.05 0.05
Additional Paid-In Capital 302.18 300.51 298.74 298.33
Retained Earnings (Accumulated Deficit) -419.6 -402.94 -391.79 -348.68
Treasury Stock - Common -0.024 -0.02 -0.02 -0.02
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total - - - -
Total Liabilities & Shareholders' Equity 22.17 38.66 60.54 77.72
Total Common Shares Outstanding 49.86 48.69 48.19 48.06
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PHAS Comments

Write your thoughts about PhaseBio Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Salgado Stanley
Salgado Stanley Oct 25, 2022 4:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jamani mm sijui kutumia mnanisaidiaje
Truth Trader
Truth Trader Jun 24, 2022 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
0.68 aim for -0-
Michael Narvadez
Michael Narvadez Aug 12, 2020 10:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello? 👀
Yury Gromushkin
Gromov Feb 21, 2020 6:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
8.5 aim 17
The Lost
The Lost Dec 25, 2019 2:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
7.35 aim for 15
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email